Oncoclínicas is present in 14 Brazilian states and the Federal District with 143 units, including clinics, hospital partnerships and a precision medicine laboratory. It operates in the entire line of cancer care, with around 2,700 specialist doctors and 7,000 employees, performing approximately 615 thousand treatments in the last 12 months.
The result of a pioneering model in the country in the management of oncology services, the Group was founded in 2010 by oncologist Bruno Ferrari with the aim of placing the patient at the center of everything, throughout their journey.
The relevance of the Oncoclínicas Group is reinforced by the exclusive partnership in Brazil with the Dana-Farber Cancer Institute, one of the most renowned cancer research and treatment centers in the world, affiliated with Harvard Medical School. Signed in 2014, the partnership aims to exchange clinical experience, focusing on continuing medical education and training programs.
In line with the objective of offering comprehensive and interdisciplinary care, close and with personalized treatment, in February 2020, the Oncoclínicas Group launched the OC Precision Medicine, a high-tech laboratory that brings together genomics and pathological analysis. Tumor genes are analyzed in somatic panels, with artificial intelligence resources, directing treatments according to the specific needs of each individual, one of the strongest trends in oncology. OC Precision Medicine allows, among other things, to study hereditary cancer syndromes and also exome sequencing, which comprises the analysis of more than 20,000 human genes.
In addition, given the challenges posed by the pandemic, as soon as telemedicine received the legal support to be adopted, the Group implemented its own platform – OC Telemedicine to support the contact between doctors and patients.